Abbott Laboratories 10-Q Summary
Business context and reporting period
Abbott Laboratories filed an unaudited Form 10-Q for the quarter and nine months ended September 30, 2020. The company operates through Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. Results were materially affected by COVID-19, which increased demand for diagnostic testing while reducing routine diagnostic volumes and cardiovascular and neuromodulation procedure volumes.
Financial performance and liquidity
| Metric | Q3 2020 | Q3 2019 | 9M 2020 | 9M 2019 |
|---|---|---|---|---|
| Net sales | $8.853 billion | $8.076 billion | $23.907 billion | $23.590 billion |
| Operating earnings | $1.495 billion | $1.198 billion | $2.925 billion | $3.143 billion |
| Net earnings | $1.232 billion | $960 million | $2.333 billion | $2.638 billion |
| Diluted EPS | $0.69 | $0.53 | $1.30 | $1.47 |
| Gross margin | 49.4% | 52.4% | 49.2% | 52.3% |
- Third-quarter sales increased 9.6%, including 10.6% growth excluding foreign exchange. Nine-month sales increased 1.3%, or 3.2% excluding foreign exchange.
- Third-quarter operating margin was approximately 16.9%, compared with 14.8% in the prior-year quarter. Nine-month operating margin was approximately 12.2%, compared with 13.3% in 2019.
- Third-quarter net margin was approximately 13.9%, compared with 11.9% in 2019. Nine-month net margin was approximately 9.8%, compared with 11.2% in 2019.
- Diagnostics sales increased 38.2% in the third quarter and 14.2% for the nine months, driven primarily by COVID-19 testing. Medical Devices sales increased 3.4% in the quarter but declined 5.6% for the nine months because of reduced procedure volumes. Established Pharmaceuticals declined 9.3% in the quarter and 4.7% for the nine months; Nutritionals increased 2.6% and 3.1%, respectively.
- COVID-19 testing-related sales totaled $1.533 billion for the first nine months, including $881 million in the third quarter.
- Net cash from operating activities was $4.103 billion for the first nine months, up from $3.720 billion in 2019. Capital expenditures were $1.498 billion, dividends paid were $1.919 billion, and net cash used in financing activities was $1.992 billion.
- Cash and cash equivalents were $4.480 billion at September 30, 2020, compared with $3.860 billion at December 31, 2019. Cash plus short-term investments totaled approximately $4.7 billion, and available credit lines were $5.0 billion.
- Short-term borrowings and current long-term debt totaled $214 million; long-term debt was $18.349 billion. Total reported debt was approximately $18.6 billion, compared with approximately $17.9 billion at year-end 2019.
- Working capital increased to $7.1 billion from $4.8 billion at December 31, 2019, partly because of higher cash, receivables, and inventory.
Material changes versus the prior comparable period
- COVID-19 diagnostics substantially offset declines in routine laboratory testing and elective cardiovascular and neuromodulation procedures.
- Gross margin declined by 300 basis points in the third quarter and 310 basis points for the nine months. Abbott attributed the decline to sales mix, pandemic-related operating inefficiencies, higher intangible amortization, an intangible asset impairment, and foreign exchange.
- Medical Devices operating earnings declined to $928 million in the third quarter from $958 million and to $2.122 billion for the nine months from $2.722 billion.
- Diagnostics operating earnings increased to $875 million in the quarter from $456 million and to $1.802 billion for the nine months from $1.356 billion.
- Other income declined year over year because of approximately $110 million of equity investment impairments during the first nine months of 2020. A $100 million litigation settlement contributed to lower SG&A expense.
- Abbott issued $1.3 billion of senior notes in June 2020 and repaid approximately $1.3 billion of euro-denominated notes at maturity in September 2020.
- The quarterly dividend increased to $0.36 per share from $0.32 per share in the prior-year periods.
Outlook, risks, contingencies, and unusual items
The filing does not provide specific full-year earnings or revenue guidance. Management stated that the duration and impact of COVID-19 remain uncertain. Procedure volumes and routine testing improved during the second and third quarters as healthcare resources returned toward normal levels, but further pandemic effects remain difficult to predict.
- Remaining performance obligations were approximately $3.6 billion in Diagnostics and $430 million in Medical Devices. Abbott expects to recognize approximately 60% within 24 months and approximately 18% in the following 12 months.
- First-nine-month tax benefits included approximately $81 million from settlement of former St. Jude Medical tax returns, $87 million of excess share-based compensation tax benefits, and $20 million of discontinued-operation tax benefits.
- Restructuring charges totaled $42 million in the first nine months, with $119 million of related restructuring accruals outstanding at September 30, 2020.
- A Medical Devices intangible asset impairment reduced assets by $148 million in the third quarter and first nine months.
- Estimated legal and environmental loss exposure ranged from approximately $85 million to $120 million, with an accrued balance of approximately $105 million. Management did not expect a material adverse effect from these matters.
- Tax authorities may reduce recorded unrecognized tax benefits by approximately $70 million to $410 million within the next twelve months, including cash adjustments.
- Abbott identified foreign exchange, regulation, competition, healthcare reimbursement, pandemic effects, product demand, litigation, tax matters, and execution of acquisitions and restructuring plans as relevant risks.
- Management concluded that disclosure controls were effective and that no material changes occurred in internal control over financial reporting during the quarter.
Facts investors should verify
- Whether COVID-19 testing demand remains sufficient to offset normalization or decline in related sales and routine diagnostics.
- The pace and durability of recovery in cardiovascular, neuromodulation, and other elective procedure volumes.
- Diagnostics segment margins and the sustainability of COVID-19-related operating earnings.
- Inventory and receivables growth, including potential credit-loss or demand risks.
- Debt maturities, refinancing plans, and the effect of interest rates and foreign exchange on cash flow.
- The treatment and recurrence potential of investment impairments, asset impairments, restructuring charges, and tax benefits.
- Progress on remaining performance obligations and the timing of related revenue recognition.